2 Information about nivolumab
|
Marketing authorisation indication |
Nivolumab (Opdivo, Bristol-Myers Squibb) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of platinum-containing therapy. |
|
Dosage in the marketing authorisation |
3 mg/kg by intravenous infusion every 2 weeks. |
|
Price |
£439 per 40‑mg vial or £1,097 per 100‑mg vial (excluding VAT; British national formulary online, accessed September 2017). The company has a commercial arrangement, which would apply if the technology had been recommended. |